Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Synergistic antitumor effects and mechanisms of KPT-330 combined with venetoclax in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

WDWeidong Ding

Discussion

Loading...

Member takes

Overview

Preclinical models reveal KPT-330 enhances venetoclax efficacy, reducing apoptosis-related resistance in AML.

Key Points

  • This research aims to evaluate the synergistic effects and mechanisms of KPT-330 combined with venetoclax in treating acute myeloid leukemia.
  • Used AML cell lines treated with KPT-330 and venetoclax to assess synergy and cell viability.
  • Conducted flow cytometry to measure apoptosis and Western blot for protein analysis.
  • Applied CRISPR-Cas9 technology to study roles of MCL1 and NOXA in treatment response.
  • Performed RNA sequencing to identify differentially expressed genes and analyzed data using Gene Ontology and KEGG.
  • Evaluated in vivo efficacy in xenograft models and conducted survival analysis.
  • KPT-330 reduced MOLM-13 cell viability by 40% at 100 nM after 48 hours.
  • Combination therapy reduced IC50 values significantly, enhancing apoptosis with 68% Annexin V-positive cells.
  • Western blot results showed significant MCL1 downregulation and increased NOXA expression upon combination treatment.
  • In vivo results indicated a 75% reduction in tumor burden with enhanced survival in xenograft models.

Cite This Study

Weidong Ding (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfa3https://doi.org/10.1182/blood-2025-6104
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax2023 · 19 citations
  2. 2Abstract 3896: MERTK inhibitor MRX-2843 sensitizes AML to venetoclax and azacitidine in preclinical models.2026
  3. 3ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells2024 · 6 citations
  4. 4Abstract 4466: Clinical-grade CK2 inhibitor CX-4945 synergistically enhances venetoclax-mediated antileukemic activity in preclinical acute myeloid leukemia models.2026
  5. 5Abstract 7218: Venetoclax triggers apoptosis and augments the effectiveness of doxorubicin against acute myeloid leukemia cells2024